MASH Trial Patients Show More Liver Scarring
Adults with fatty liver disease may have less inflammation on treatment but more advanced fibrosis than before.
Updated on Nov. 7, 2026 in Diabetes

Patients screened for MASH (metabolic dysfunction-associated steatohepatitis) trials are showing less disease activity but more advanced liver fibrosis, according to findings presented at AASLD's The Liver Meeting 2026. Researchers say the shift reflects both improved screening methods and the effects of GLP-1 medications on inflammation.
Why it matters
As GLP-1 drugs lower inflammation in the liver, trials are enrolling patients whose disease is more scarred but less active, which could change how new treatments are tested and judged. Better tools to identify patients with advanced scarring may help clinicians catch liver disease that could otherwise go unnoticed.
This is an analysis of screening data from patients enrolled in MASH trials, presented by Dunn at AASLD's The Liver Meeting 2026. SMART-MASH identified about a third more patients with cirrhosis than the Agile 4 tool, and patients had taken GLP-1 drugs for a median of about 1 year; no effective tool yet exists to identify ballooning, the marker of disease activity.
The players
AASLD (American Association for the Study of Liver Diseases)
AASLD is the leading professional society for hepatologists and liver researchers, and hosts The Liver Meeting, a major annual conference on liver disease.
University of Kansas Medical Center
The University of Kansas Medical Center is an academic medical institution whose researchers contribute to clinical and translational liver disease studies.
The details
Trial screening protocols now use noninvasive tests such as vibration-controlled transient elastography (VCTE) and the ELF blood test to detect scarring, which has made it easier to enroll patients with fibrosis. The SMART-MASH tool combines these approaches, using VCTE alone for a third of patients, VCTE plus ELF for another third, and point-of-care labs for the rest. GLP-1 medications reduce the inflammatory ballooning seen in the liver over time, while scarring changes more slowly, so patients who have taken these drugs long enough can show improved activity scores without a matching drop in fibrosis.
Timeline
2026: Dunn presented the findings at AASLD's The Liver Meeting 2026.
Health Landscape
Metabolic dysfunction-associated steatohepatitis, or MASH, has become a major focus of drug development as GLP-1 medications move into liver disease treatment. This finding suggests that trial populations are changing as these drugs take effect, which may affect how future MASH therapies are evaluated.
If you have fatty liver disease or metabolic risk factors, ask your doctor whether a liver fibrosis assessment such as elastography or a blood-based fibrosis test is appropriate for you. Scarring can progress without symptoms, so routine liver screening is worth discussing with your physician.
The takeaway
Less visible liver inflammation does not always mean less serious disease, since scarring can advance even as activity improves. Ask your doctor about fibrosis screening if you have fatty liver disease or metabolic risk factors.
Further reading
For broader context on the metabolic conditions behind liver disease, explore our Diabetes coverage.


